

(U)

AD-A221 845

DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

2b. DECLASSIFICATION/DOWNGRADING SCHEDULE N/A		1b. RESTRICTIVE MARKINGS N/A	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) Kansas State University		3. DISTRIBUTION/AVAILABILITY OF REPORT Distribution Unlimited	
6a. NAME OF PERFORMING ORGANIZATION Kansas State University	6b. OFFICE SYMBOL (If applicable) N/A	5. MONITORING ORGANIZATION REPORT NUMBER(S) N/A	
6c. ADDRESS (City, State, and ZIP Code) Division of Biology, Ackert Hall Manhattan, KS 66506		7a. NAME OF MONITORING ORGANIZATION Office of Naval Research	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION Office of Naval Research		7b. ADDRESS (City, State, and ZIP Code) 800 No. Quincy Street Arlington, VA 22217-5000	
8b. OFFICE SYMBOL (If applicable) ONR		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER N00014-87-K-0217	
8c. ADDRESS (City, State, and ZIP Code) 800 No. Quincy Street Arlington, VA 22217-5000		10. SOURCE OF FUNDING NUMBERS	
		PROGRAM ELEMENT NO. 61153N	PROJECT NO. RR04108
		TASK NO. 441f722	WORK UNIT ACCESSION NO.
11. TITLE (Include Security Classification) (U) The role of neuropeptides in persistent virus infections of the central nervous system.			
12. PERSONAL AUTHOR(S) Johnson, Terry C.			
13a. TYPE OF REPORT FINAL	13b. TIME COVERED FROM 3/1/87 TO 11/30/89	14. DATE OF REPORT (Year, Month, Day) May 10, 1990	15. PAGE COUNT 19
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	
		opioids, lymphocytes, infections, nervous system, virus, immunity, neuropeptides, JTS	
19. ABSTRACT (Continue on reverse if necessary and identify by block number)			
A temperature-sensitive (ts) mutant of vesicular stomatitis virus (VSV), tsG31 KS5, engendered a slowly progressive paralytic central nervous system (CNS) disease that killed all Balb/c nude mice within 28 days. Reconstitution of nude mice with 10⁷ syngeneic splenocytes 24 h before intracerebral inoculation with tsG31 KS5 VSV, however, protected 92% of the animals from death. When these reconstituted animals were injected intracerebroventricularly with 14 pmol of β-endorphin 24 h after reconstitution with splenocytes and 24 h before inoculation with tsG31 KS5 VSV, only 72% of the animals survived. Furthermore, whereas 40% of the afflicted reconstituted nude mice given intracerebroventricular injections of sterile water were able to recover from the symptoms of disease, those surviving animals which received β-endorphin were unable to			
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ☒ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION (U)	
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. J.A. Majde		22b. TELEPHONE (Include Area Code) (202) 696-4055	22c. OFFICE SYMBOL ONR

do so. A single intravenous injection of 14 pmole β -endorphin, or repeated postinfection administration of 28 pmol of β -endorphin intravenously into nude mice reconstituted with syngeneic splenocytes, which were pretreated with β -endorphin, did not alter the course of CNS disease induced by tsG31 KS5 VSV. The effect induced by intracerebroventricular injection of

Accession For

NTIS GRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	

By _____

Organization/ _____

Availability Codes

Avail and/or _____

Unannounced _____

A-1



FINAL REPORT

The Role of Neuropeptides in Persistent Virus Infections of the Central Nervous System

ONR Contract No. N00014-87-K-0217

A. Introduction

β -endorphin has been shown to have many different effects on immune cells. On the cellular level, the effects of β -endorphin on immune cells are mediated via two different classes of receptors. Through opioid receptors, β -endorphin enhances the cytotoxicity of natural killer cells (Matthews et al., 1983) and mediates chemotaxis of human blood mononuclear cells (Van Epps and Saland, 1984; Ruff et al., 1985). Through non-opioid receptors (Hazum et al., 1979; Schweigerer et al., 1982), β -endorphin suppresses stimulation of lymphocytes (McCain et al., 1982; Deitch et al., 1988), and has been shown to enhance proliferation of lymphocytes (Gilman et al., 1982).

Although evidence points to a potential role for β -endorphin in modulating immune responses, there is a paucity of information concerning the effect of β -endorphin on the overall clinical progress of infectious disease in vivo. We have demonstrated that β -endorphin dramatically altered the course of CNS disease in two genetically different strains of mice (Doll and Johnson, 1989). β -endorphin, however, was unable to alter the course of CNS disease in Balb/c (nu/nu) nude mice (Doll and Johnson, 1989). Nude mice have no thymus and, thus, lack a full repertoire of mature, differentiated T-cells (Kindred, 1981). Therefore, we reasoned that the ability of β -endorphin in altering the course of CNS disease in Balb/c mice may have been due to an immune-neuropeptide interaction, and the failure of β -endorphin to do so in nude mice may have been due to a lack of appropriate immune targets for neuropeptide action. However, nude mice reconstituted with syngeneic splenocytes, which are rich in mature T-cells, and infected with ts VSV should be susceptible to the action of β -endorphin and should undergo a more severe clinical disease. In this **final report** we show that a single intracerebroventricular injection of β -endorphin into nude mice can indeed alter the course of CNS disease induced by ts VSV. We also explore with analogs of β -endorphin the specificity of the response and the possible receptors through which this effect might be mediated.

B. Research Results

1) Materials and methods

a. Subjects

Balb/c (+/+) and Balb/c nude (nu/nu) mice were acquired from Harlan Sprague Dawley (Indianapolis, IN, U.S.A.). Three to four week old male Balb/c nude were used, and all the mice had free access to sterile food and water. The mice were maintained throughout the experiments in an animal Stay-Clean unit from Lab products (Maywood, NJ, U.S.A.).

b. Virus and inoculations

TsG31 KS5 VSV was a double-cloned isolate, plaque purified from tsG31 VSV, purified on sucrose gradients, and stocks were prepared as described previously (Rabinowitz et al., 1976). Mice were lightly anesthetized with ether and infected intracerebrally with 100 plaque forming units (pfu) of virus in 30 μ l of Hanks' balanced salt solution (HBSS).

c. Injection of neuropeptides

Prior to injection, β -endorphin, β -endorphin-(1-27), and des-tyr-endorphin (synthetic human; Sigma Chemical Co., St. Louis, MO, U.S.A.) and naloxone (Sigma Chemical Co., St. Louis, MO, U.S.A.) were solubilized in sterile, distilled water. The amounts per mouse of β -endorphin, 14 pmol; β -endorphin-(1-27), 330 pmol; des-tyr-endorphin, 29 pmol; and naloxone, 1220 pmol, were diluted in 10 μ l of sterile, distilled water. The animals were lightly anesthetized with ether and the neuropeptides were injected intracerebroventricularly with a Hamilton syringe equipped with a 30 gauge needle. Control animals received 10 μ l of sterile, distilled water.

d. Splenocytes

Syngeneic splenocytes were isolated from the spleens of 2 month old Balb/c (+/+) mice by nylon wool separation as described previously (Julius et al., 1973). Briefly, the spleens were removed from Balb/c (+/+) by sterile dissection, and were suspended by pressing them through a fine stainless steel mesh submerged in HBSS. The cell suspensions were centrifuged (250 g for 3 min) and resuspended in cold Tris-buffered isotonic ammonium chloride to lyse erythrocytes. After a 10 min incubation at 0°C, the splenocytes were washed 3 times with HBSS, resuspended in Dulbecco's modified eagle medium supplemented with 10% fetal calf serum (DMEM/FCS), then were incubated on 30 ml nylon wool columns for 1 hr at 38°C. The splenocytes were collected from the columns in DMEM/FCS, and washed once in HBSS. After washing, the cells were resuspended in a concentration of 10^8 per ml then 100 μ l were injected intravenously into the tails of nude mice with a 30 gauge needle.

e. Clinical status of disease

Mice were checked daily for the duration of the experiments and they were graded by examination on a scale from 0 to 5, with grade 0 representing complete health, grade 1 representing initial signs of disease, grade 2 as animals with difficulty in walking or a clumsy gait, grade 3 as those with one hind limb paralyzed, grade 4 representing as animals with both hind limbs paralyzed, and grade 5 representing death. Animals at grade 2 or above were considered to be diseased, and only those animals at grade 2 or above that improved to grades 1 or 0 were considered to have recovered from the disease.

2) Experimental data

Balb/c nude mice infected with 100 pfu of tsG31 KS5 VSV undergo a CNS disease that resulted in wasting, loss of appetite, hindlimb paralysis and, ultimately, in the death of all the animals within 28 days. These animals, however, can be protected by reconstitution with syngeneic splenocytes. Reconstitution of nude mice with 10^7 nylon wool nonadherent syngeneic splenocytes prior to infection resulted in the protection of 92% of the animals from death (Fig. 1).

Since we were able to protect the animals from death, we next wanted to investigate the effect of β -endorphin on the course of CNS disease as measured by survival in reconstituted nude mice infected with tsG31 KS5 VSV. A single injection of 14 pmol of β -endorphin (50 ng) administered intracerebroventricularly into reconstituted nude mice altered the course of clinical disease induced by tsG31 KS5 VSV, causing 28% more animals to die than those animals which received injections of sterile water (Fig. 2). This effect was consistently repeatable, and analyses of eight independent experiments revealed there to be a significant statistical difference between the experimental and control populations -- the p values from a one-tailed, unpaired, t-test at days 15 and 28 postinfection were 0.007 and 0.01, respectively. Increasing the level of β -endorphin from 14 pmol to 28 pmol or 140 pmol, however, had the same degree of influence on the course of disease and on the amount of death induced (data not shown). Unlike the enduring hypothermia that we previously had reported with 28 pmol (100 ng) of β -endorphin (Doll and Johnson, 1989), 14 pmol of β -endorphin did not produce a lasting hypothermia in Balb/c mice (Table 1), indicating that hypothermia was not responsible for the increased virulence.

In contrast to injection of β -endorphin into the brain, a single intravenous injection of 14 pmol of β -endorphin into nine nude mice 24 h before reconstitution with 10^7 splenocytes, and 24 h prior to infection with 100 pfu tsG31 KS5 VSV, did not alter the course of CNS disease. Eighty-nine percent of the animals in this experiment survived the virus infection (data not shown). Furthermore, pretreatment of splenocytes with β -endorphin and re-

peated intravenous injections of β -endorphin also did not alter the ability of nude mice to survive the CNS disease induced by tsG31 KS5 VSV. Syngeneic splenocytes, 10^8 /ml of HBSS, were pre-incubated with 28 pmol of β -endorphin for 30 min at 25°C, washed 3 times with HBSS and 10^7 cells in 100 μ l of HBSS were then intravenously injected into nude mice. Two days later, the mice were infected intracerebrally with 100 pfu tsG31 KS5 VSV, and they were given repeated intravenous injections of 28 pmol of β -endorphin in 100 μ l of HBSS every other day up to 7 days post-infection. All of the animals survived (data not shown).

To further elucidate the effect of β -endorphin on the CNS disease induced by tsG31 KS5 VSV on reconstituted nude mice, we daily monitored, throughout the experiment, the clinical symptoms of animals injected with either sterile water or β -endorphin. By day 12 postinfection, surprisingly, approximately the same amount of disease was engendered in both the group of animals receiving sterile water and the group receiving 14 pmol of β -endorphin. However, whereas 40% of the afflicted animals receiving intracerebroventricular injections of sterile water recovered by day 32, the surviving afflicted animals which received 14 pmol intracerebroventricular injections of β -endorphin did not appreciably recover from the disease (Fig. 3).

To investigate the possibility that the effect was being mediated through opioid receptors, we employed naloxone, the classic opioid antagonist, and β -endorphin-(1-27), a naturally occurring fragment of β -endorphin that can be used to antagonize β -endorphin. Reconstituted nude mice were injected intracerebroventricularly with either 1220 pmol of naloxone alone or simultaneously with 1220 pmol of naloxone and 14 pmol of β -endorphin. Similar to sterile water controls, 90% of the animals receiving both β -endorphin and naloxone survived challenge with 100 pfu tsG31 KS5 VSV (Table 2), and two-thirds of those afflicted animals were able to ameliorate the clinical status of their disease (Table 3). All of the animals receiving only naloxone survived the disease, and 33% of those afflicted were able to recover from the disease (Table 2).

Reconstituted nude mice also were injected intracerebroventricularly with either 330 pmol of β -endorphin-(1-27) or simultaneously with 330 pmol of β -endorphin-(1-27) and 14 pmol of β -endorphin. Unlike naloxone, however, β -endorphin-(1-27) was unable to antagonize the effects of β -endorphin as determined by survival and the clinical status of disease induced by tsG31 KS5 VSV in reconstituted nude mice. Similar to animals receiving only 14 pmol of β -endorphin, 28% of the animals receiving both β -endorphin and β -endorphin-(1-27) succumbed to the disease (Table 2), and these animals were unable to improve appreciably the clinical status of their disease (Table 3). All of the animals receiving only β -endorphin-(1-27) survived the disease (Table 2), and nearly one-fourth of those afflicted were able to ameliorate the clinical status of their disease (Table 3).

In order to determine whether the observed effect of β -endorphin on the course of CNS disease in reconstituted nude mice was specific to β -endorphin alone or perhaps to a more general phenomenon of psychoactive neuropeptides, we employed des-tyr-endorphin, a naturally occurring psychoactive peptide composed of the 2nd through 15th amino acids of β -endorphin. When 29 pmol of des-tyr-endorphin was injected intracerebroventricularly into reconstituted nude mice 24 hours prior to infection with tsG31 KS5 VSV, des-tyr-endorphin increased the lethality of the disease very similar to that observed with β -endorphin (Table 2). However, unlike β -endorphin, the surviving animals receiving des-tyr-endorphin were able to recover from the disease as determined by clinical symptoms. With respect to this criterion, they responded very much like animals receiving sterile water injections as 39% of the afflicted animals injected with 29 pmol of des-tyr-endorphin were able to recover from the disease (Table 3).

3) Discussion

Just 100 pfu of tsG31 KS5 VSV, a more natural dose of virus, was able to induce an infection similar to that which we previously had reported with 10^4 pfu of the same virus (Doll and Johnson, 1989). Nude mice infected with 100 pfu tsG31 KS5 VSV underwent a slowly progressive disease that killed all the mice within 28 days. Reconstitution of nude mice with 10^7 syngeneic splenocytes, however, protected 92% of the animals from death (Fig. 1). When these reconstituted animals were intracerebroventricularly injected with β -endorphin 24 hours prior to infection with tsG31 KS5 VSV, an alteration in the course of disease occurred. β -endorphin caused death in 28% of the animals and it also prevented the surviving afflicted animals from ameliorating the clinical status of their disease.

It is apparent, however, that hypothermia was not responsible for the effect of β -endorphin on the course of CNS disease induced by tsG31 KS5 VSV as we had previously believed. First, the dose of 50 ng of β -endorphin used in the present study altered the course of CNS disease without producing any hypothermia (Table 1). Secondly, previous results from our lab also indicated no detectable effect of β -endorphin on the CNS disease in unreconstituted nude mice even though the 100 ng dose given them produced a lasting hypothermia (Doll and Johnson, 1989). Furthermore, it is evident that, since β -endorphin had no effect on the course of CNS disease in unreconstituted nude mice (Doll and Johnson, 1989), but did in reconstituted nude mice, β -endorphin must have elicited its effect, either directly or indirectly, on the immune system, and an indirect effect of β -endorphin on the immune system is most likely. We observed no effect on the course of CNS disease induced by tsG31 KS5 VSV with a single intravenous injection of β -endorphin, or when β -endorphin was applied directly to splenocytes before reconstitution of nude mice and then was repeatedly injected intravenously into these same animals for up to 7 days postinfection.

In order to determine whether the action of β -endorphin was mediated through opioid receptors, we employed the classic opioid antagonist naloxone. Naloxone has greatest affinity for the μ opioid receptor, but at high concentrations, i.e. a molar ratio of 85 nmol naloxone to 1 nmol β -endorphin, it will block both the μ and δ opioid receptors (Hammonds et al., 1987), which are the opioid sites to which β -endorphin binds. At this ratio, naloxone did block the effect of β -endorphin on the course of CNS disease induced by tsG31 KS5 VSV, as determined by survival and the ability of afflicted animals to recover from disease, indicating that the effect was mediated through opioid receptors. Naloxone alone did not alter the course of CNS disease induced by tsG31 KS5 VSV.

Surprisingly, we could not block the effect of β -endorphin with β -endorphin-(1-27), a naturally occurring fragment of β -endorphin that has been reported to bind the same μ and σ opioid receptors as does β -endorphin (Nicholas et al., 1985) and to be 4 times more potent in antagonizing β -endorphin's opiate effects (Nicholas and Li, 1984; Suh et al., 1987; Bals-Kubik et al., 1988). Why naloxone should block the effect of β -endorphin and β -endorphin-(1-27) would not, is unclear. One possible explanation is that studies using β -endorphin-(1-27) as an antagonist of β -endorphin have been limited to 3 hours (Suh et al., 1987); thus, β -endorphin-(1-27) may be less stable than naloxone and, unable to maintain its antagonism throughout the 24 h between injection of neuropeptide and challenge with virus in our model. All of the animals receiving β -endorphin-(1-27) alone survived challenge with tsG31 KS5 VSV and were able to ameliorate appreciably the clinical status of their disease, i.e. they behaved very much like animals receiving intracerebroventricular injections of sterile water.

It is apparent from the results obtained from animals injected only with either naloxone or β -endorphin-(1-27), that merely occupying the opioid receptor does not elicit an effect on the course of CNS disease induced by tsG31 KS5 VSV, i.e. only a psychoactive molecule will perform. Des-tyr-endorphin, a psychoactive peptide, altered the course of CNS disease induced by tsG31 KS5 VSV. Des-tyr-endorphin corresponds to the 2nd through 15th amino acids of β -endorphin, and has been shown to extinguish active avoidance behavior, to attenuate passive avoidance behavior in rats (De Wied et al., 1978), and to ameliorate symptoms of schizophrenia (De Jongh et al., 1982). A single intracerebroventricular injection of 29 pmol of des-tyr-endorphin lowered the amount of survival of reconstituted nude mice challenged with tsG31 KS5 VSV, which was similar to the effect observed with β -endorphin on survival of reconstituted nude mice from the CNS disease induced by tsG31 KS5 VSV. Unlike animals receiving β -endorphin, however, the surviving animals receiving des-tyr-endorphin were able to improve the clinical status of their disease (Table 3). Why des-tyr-endorphin elicited its effect on survival like β -endorphin, but not on the clinical status of the CNS disease, may be that des-tyr-endorphin mediated its effect via some other mechanism. It has been shown that removing the N-terminal amino

acid tyrosine from met-enkephalin, which corresponds to the first five amino acids of β -endorphin, abolishes met-enkephalin's ability to bind to opioid receptors (Frederickson, 1977). Since des-tyr-endorphin is missing this same amino terminus, it also must be unable to bind to the opioid receptor (De Wied et al., 1978).

Considerable anecdotal evidence exists which suggests a role for neuropeptides on the immunomodulation of disease. Clinicians have long noticed that opiate addicts have increased risk and severity of infections (Briggs et al., 1967; Hussey and Katz, 1950; Olsson and Romansky, 1962). Clinical evidence from mice has also suggested that stress, which is modulated by neuropeptides (Stein et al., 1985; Grossman, 1988), can increase susceptibility to infection (Riley, 1981). The implicit message in this evidence is that neuropeptides may alter host immunity to infection, but proving such a link has been difficult.

The work done on elucidating the interaction between the neuroendocrine and immune systems during the course of a disease has been approached in two different ways -- studying the effects of neuropeptides on immunocytes and studying the effects of neuropeptides on the course of infectious disease. In the first approach, many in vitro and in vivo studies have shown that neuropeptides have an effect on immunocytes. As examples, β -endorphin has been shown to enhance (Gilman et al., 1982) and suppress (McCain et al., 1982) proliferation of mitogen stimulated lymphocytes, and to bind to the terminal complex of human complement (Schweigerer et al., 1982); Met-enkephalin has been shown to stimulate human blood mononuclear cell chemotaxis (Van Epps and Saland, 1984), and to suppress and enhance immune response in rats (Jankovic and Maric, 1987). Bombesin has been found in human mononuclear cells and in alveolar macrophages (Wiedermann et al., 1986). Lymphocytes also appear to be able to produce endorphins, lending further evidence that neuropeptides may serve as messengers between the immune and nervous systems (Smith et al., 1985).

The second approach has used an infected murine model to show that injection of a neuropeptide can influence the course of a disease in vivo. This was accomplished first by Doll and Johnson (1985; 1989) who showed that neurotensin and β -endorphin altered the course of disease induced by temperature-sensitive VSV in Swiss outbred and Balb/c mice. Since then, Faith et al. (1987) were able to lessen the severity of disease induced by herpes simplex virus type 2 in A/J mice. In a similar manner Huprikar et al. (1988) used bombesin to alter the course of disease induced by a temperature-sensitive isolate of VSV.

Neither of these two approaches, however, demonstrated a firm link between the neuroendocrine and immune systems in the host response to disease. Those demonstrations of the effects of neuropeptides on immunocytes were in the absence of a disease process, while those experiments showing an effect of neuropep-

tides on the course of a disease offered no experimental evidence as to whether or not the effect was due to an immune-neuropeptide interaction. The present study, provides a model which demonstrates that some form of communication indeed does exist between the neuroendocrine and immune systems that influences the clinical course of an infectious disease. First, β -endorphin exerted an effect on the immune system of reconstituted nude mice, although it was previously shown to be unable to do so in unreconstituted nude mice (Doll and Johnson, 1989). Second, the effect appeared to be indirect, since a single intravenous injection of β -endorphin or incubation of splenocytes with β -endorphin, followed by intravenous injection of β -endorphin in the reconstituted animal, did not influence the course of disease. And third, this effect was mediated via opioid receptors, since the effect was naloxone reversible.

4) References

- Bals-Kubik, R., Herz, A., and Shippenberg, T. S. (1988) β -endorphin-(1-27) is a naturally occurring antagonist of the reinforcing effects of opioids. *Arch. Pharmacol.* 338, 392-396.
- Briggs, J. H., McKerron, C. G., Souhami, R. L., Taylor, and D. J. E., Andrews, H. (1967) Severe systemic infections complicating mainline heroin addiction. *Lancet* 2 1227-1231.
- Deitch, E. A., Xu, D., and Bridges, R. M. (1988) Opioids modulate human neutrophil and lymphocyte function: Thermal injury alters plasma β -endorphin levels. *Surgery* 104, 41-48.
- De Jongh, B. M., Verhoeven, W. M. A., Van Ree, J. M., De Wied, D., and Van Rood, J. J. (1982) HLA, and the response to treatment with τ type endorphins in schizophrenia. *J. Immunogenetics* 9, 381-388.
- De Wied, D., Kovacs, G. L., Bohus, B., Van Ree, J. M., and Grevén, H. M. (1978) Neuroleptic activity of the neuropeptide β -LPH₆₂₋₇₇. *Eur. J. Pharmacol.* 49, 427-436.
- Doll, S. C. and Johnson, T. C. (1989) β -endorphin alters a viral induced central nervous system disease in normal mice but not in nude mice. *J. Neuroimmunol.* 24, 47-53.
- Faith, R. E., Murgo, A. J., Clinkscales, C. W., and Plotnikoff, N. P. (1987) Enhancement of host resistance to viral and tumor challenge by treatment with methionine-enkephalin. *Ann. N. Y. Acad. Sci.* 496, 137-145.
- Frederickson, R. C. A. (1977) Enkephalin pentapeptides -- a review of current evidence for a physiological role in vertebrate neurotransmission. *Life Sci.* 21, 23-41.

- Gilman, S. C., Schwartz, J. M., Milner, R. J., Bloom, F. E., and Feldman, J. D. (1982) β -endorphin enhances lymphocyte proliferative responses. *Proc. Natl. Acad. Sci. USA.* 79, 4226-4230.
- Grossman, A. (1988) Opioids and stress in man. *J. Endocrin.* 119, 377-381.
- Hammonds, G. H., Nicolas, P., and Li, C. H. (1984) β -endorphin-(1-27) is an antagonist of β -endorphin analgesia. *Proc. Natl. Acad. Sci.* 81, 1389-1390.
- Hazum, E., Chang, K., and Cuatrecasas, P. (1979) Specific non-opiate receptors for β -endorphin. *Science* 205, 1033-1035.
- Huprikar, J., Dal Canto, M. C., and Rabinowitz, S. G. (1989) Altered neurovirulence of temperature-sensitive vesicular stomatitis virus mutant in a murine model by inoculation of bombesin: a neuropeptide. *J. Neur. Sci.* 89, 279-288.
- Hussey, H. H. and Katz, S. (1950) Infections resulting from narcotic addiction. *Am. J. Med.* 9, 186-193.
- Jankovic, B. D. and Maric, D. (1987) Enkephalins and immunity. I: In vivo suppression and potentiation of humoral immune response. *Ann. N. Y. Acad. Sci.* 496, 115-125.
- Julius, H., Simpson, E., and Herzenberg, L. A. (1973) A rapid method for the isolation of functional thymus-derived murine lymphocytes. *Eur. J. Immunol.* 3, 645-649.
- Kindred, B. (1981) Deficient and sufficient immune systems in the nude mice, in *Immunologic Defects in Laboratory Animals*, (Gershwin, M. E. and Merchant, B., eds.), pp. 215-265, Plenum Press, New York.
- Matthews, P. M., Froelich, C. J., Sibbitt, W. L., and Bankhurst, A. D. (1983) Enhancement of natural cytotoxicity by β -endorphin. *J. Immunol.* 130, 1658-1662.
- McCain, H. W., Lamster, I. B., Bozzone, J. M., and Grbic, J. T. (1982) β -endorphin modulates human immune activity via non-opiate receptor mechanisms. *Life Sci.* 31, 1619-1624.
- Nicolas, P., Hammonds, R. G., and Li, C. H. (1984) β -endorphin-induced analgesia is inhibited by synthetic analogs of β -endorphin. *Proc. Natl. Acad. Sci. USA* 81, 3074-3077.
- Nicolas, P. and Li, C. H. (1985) β -endorphin-(1-27) is a naturally occurring antagonist to etorphine-induced analgesia. *Proc. Natl. Acad. Sci. USA* 82, 3178-3181.

- Olsson, R. A. and Romansky, M. J. (1962) Staphylococcal tricuspid endocarditis in heroin addicts. *Ann. Int. Med.* 57, 755-762.
- Rabinowitz, S. G., Dal Canto, M. C., and Johnson, T. C. (1976) Comparison of central nervous system disease produced by wild-type and temperature-sensitive mutants of vesicular stomatitis virus. *Infect. Immun.* 13, 1242-1249.
- Riley, V. (1981) Psychoneuroendocrine influences on immuno-competence and neoplasia. *Science* 212, 1100-1109.
- Ruff, M. R., Wahl, S. M., Mergenhagen, S., and Pert, C. B. (1985) Opiate receptor-mediated chemotaxis of human monocytes. *Neuropeptides* 5, 363-366.
- Schweigerer, L., Bhakdi, S., and Teschemacher, H. (1982) Specific non-opiate binding sites for human β -endorphin on the terminal complex of human complement. *Nature* 296, 572-574.
- Smith, E. M., Harbour-McMenamin, D., and Blalock, J. E. (1985) Lymphocyte production of endorphins and endorphin-mediated immunoregulatory activity. *J. Immunol.* 135, 779s-781s.
- Stein, M., Keller, S. E., and Schleifer, S. J. (1985) Stress and immunomodulation: The role of depression and neuroendocrine function. *J. Immunol.* 135, 827s-833s.
- Suh, H. H., Tseng, L., and Li, C. H. (1987) β -endorphin- (1-27) antagonizes β -endorphin-induced hypothermia in mice. *Peptides* 8, 123-126.
- Van Epps, D. E. and Saland, L. (1984) β -endorphin and met-enkephalin stimulate human peripheral blood mononuclear cell chemotaxis. *J. Immunol.* 132, 3046-3053.
- Wiedermann, C. J., Goldman, M. E., Plutchak, J. J., Sertle, K., Kalinger, M. A., Johnston-Early, M. H., Cohen, M. H., Ruff, M. R., and Pert, C. B. (1986) Bombesin in human and guinea pig alveolar macrophages. *J. Immunol.* 137, 3928-3932.

Figure legends

Fig. 1. Survival of nude mice infected with tsG31-KS5 VSV. Mice were infected intracerebrally with 100 pfu of virus one day after reconstitution with 10^7 syngeneic splenocytes (0), or were infected with 100 pfu of virus only (0). The reconstituted group contained 54 animals (eight experiments), and the unreconstituted group contained 25 (four experiments).

Fig. 2. Survival of reconstituted nude mice treated with β -endorphin before infection with tsG31-KS5 VSV. Mice were injected intracerebroventricularly with 14 pmol β -endorphin 24 h after reconstitution with 10^7 syngeneic splenocytes and 24 h prior to infection with 100 pfu tsG31-KS5 VSV (0). Or reconstituted nude mice were given intracerebroventricular injections of sterile water and infected as above (0). Each group contained 18 mice (two experiments), and the vertical bars represent the standard errors. At 15 days and 28 days postinfection, $p = 0.04$ as measured by a one-tailed, unpaired t-test.

Fig. 3. Intracerebroventricular injection of β -endorphin prevents reconstituted nude mice from ameliorating the clinical status of the disease induced by tsG31-KS5 VSV. Mice received either an injection of 10 μ l of sterile water (0) or 14 pmol β -endorphin (0) 24 h after reconstitution with syngeneic splenocytes and 24 h prior to challenge with 100 pfu virus. The percentage of mice paralyzed or dead was plotted every 4 days for 32 days. The β -endorphin group contained 61 animals (eight experiments), and the water injected group contained 54 animals (eight experiments). The vertical bars represent the standard errors. At 24 days and 32 days postinfection, as measured with a one-tailed, unpaired t-test, $p = 0.03$ and 0.02, respectively.

TABLE 1.

EFFECT OF β -ENDORPHIN ON THE CORE TEMPERATURE OF BALB/C MICE.

		<u>Time After Injection</u>		
<u>Compound</u> ^a	<u>Amount</u>	<u>0 h</u>	<u>12 h</u>	<u>24 h</u>
[Temperature (°C ± S.D.)] ^b				
Sterile water	10 μl	38.39 ± 0.31	38.16 ± 0.49	37.69 ± 0.36
β-endorphin	14 pmol	37.48 ± 0.42	38.03 ± 0.35	37.60 ± 0.27

^a Balb/c mice were intracerebroventricularly injected with the indicated amount of β -endorphin in 10 μl of sterile water or 10 μl of sterile water alone.

^b The core temperatures of the mice were taken every 4 h up to 24 h.

Each group contained 10 mice.

TABLE 2.

THE EFFECT OF ANALOGS AND ANTAGONISTS OF β -ENDORPHIN ON SURVIVAL FROM CNS DISEASE

<u>Compound^a</u>	<u>Amount</u>	<u>Exper.</u> (number)	<u>Animals</u> (number)	<u>Days Postinfection</u>			
				<u>5</u>	<u>10</u>	<u>15</u>	<u>20</u>
				<u>Survival</u> (%)			
Sterile water	10 μ l	8	54	100	98	96	92
Naloxone	1220 pmol	1	5	100	100	100	100
β -endorphin + naloxone	14 pmol and 1220 pmol	2	19	100	89	89	89
β -endorphin-(1-27)	330 pmol	2	23	100	100	100	100
β -endorphin + β -endorphin-(1-27)	14 pmol and 330 pmol	2	18	100	77*	72*	72*
Des-tyr-endorphin	29 pmol	3	27	97	85*	74*	74*

^a Nude mice were injected intracerebroventricularly with the indicated amounts of analog or antagonist in 10 μ l of sterile water 24 h after reconstitution with 10^7 syngeneic splenocytes and 24 h before challenge with 100 pfu tsG31 KS5 VSV.

* Indicates values significantly different from water injected control group, $p = \leq 0.03$, measured by a one-tailed, unpaired t-test.

TABLE 3.


THE EFFECT OF ANALOGS AND ANTAGONISTS OF β -ENDORPHIN ON THE CLINICAL STATUS OF DISEASE.


<u>Compound^a</u>	<u>Amount</u>	<u>Exper.</u> (number)	<u>Animals</u> (number)	<u>Days Postinfection</u>				<u>Recovery^b</u> (%)
				8	12	16	32	
Sterile water	10 μ l	8	54	46	66	60	40	39
Naloxone	1220 pmol	1	5	0	60	60	40	33
β -endorphin + naloxone	14 pmol and 1220 pmol	2	19	37	79	63	53	33
β -endorphin-(1-27)	330 pmol	2	23	22	65	78	60	23
β -endorphin + β -endorphin-(1-27)	14 pmol and 330 pmol	2	18	67	94	94*	89*	5
Des-tyr-endorphin	29 pmol	3	27	63	82	85*	52	39


^a Nude mice were intracerebroventricularly injected with the indicated amounts of analog or antagonist 24 h after reconstitution with 10⁷ syngeneic splenocytes and 24 h prior to inoculation with 100 pfu tsG31 KS5 VSV.

^b Mice were monitored daily for clinical symptoms and the percent of animals paralyzed or dead was calculated. Percent recovery was determined by dividing the difference between the peak amount of disease and the amount of disease at day 32 by the peak amount of disease. Only those afflicted animals that fully overcame the paralysis were considered to have recovered from the disease.

* Indicates values significantly different from water injected control group, $p = \leq 0.03$, measured by a one-tailed, unpaired t-test.







C. Publications

- Doll, S.C., and Johnson, T.C. 1988. Reconstitution with T lymphocytes protects nude mice from a central nervous system disorder induced by a temperature-sensitive vesicular stomatitis virus. *J. Gen. Virol.* 69: 1969-1977.
- Doll, S.C., and Johnson, T.C. 1988. A study of persistent viral infections using nude mice and a temperature-sensitive mutant of vesicular stomatitis virus. *N.Y. Acad. Sci.* 540: 678-680.
- Doll, S.C., and Johnson, T.C. 1989. β -endorphin alters a viral induced central nervous system disease in normal mice but not in nude mice. *J. Neuroimmunol.* 24: 47-53.
- Doll, S.C., and Johnson, T.C. 1990. The nucleocapsid protein of vesicular stomatitis virus isolated from the brains of nude mice is responsible for abated viral RNA synthesis at the normal body temperature of mice. *J. Gen. Virol.* 71: 29-36.
- Hummer, H.J., Coons, W.J., Watts, S.A., and Johnson, T.C. 1990. β -endorphin alters the course of CNS disease induced by a temperature-sensitive vesicular stomatitis virus in reconstituted nude mice. *J. Neuroimmunol.* (in press).

D. Abstracts and presented papers

- Johnson, T.C. 1988. Neuropeptides and virus infections. *Trans. Amer. Soc. Neurochem.* 19: 196.
- Johnson, T.C. 1988. Neuropeptides and viral diseases of the central nervous system. Presented before the Office of Naval Research Meeting on Behavioral Immunology.
- Hummer, H., Watts, S., Coons, W. and Johnson, T. 1988. Neuropeptides alter the course of disease induced by vesicular stomatitis virus. 31st West Central States Biochemistry Conference.
- Johnson, T.C., Hummer, H.J. and Coons, W.J. 1989. Neuropeptides, immunology and viral diseases of the central nervous system. American Society for Gravitational and Space Biology.
- Gerren, R.A. and Johnson, T.C. 1989. Electrophysiologic responses used to measure the progress of viral disease in the central nervous system. American Society for Gravitational and Space Biology.

- Coons, W.J., Hummer, H.J. and Johnson, T.C. 1989. A neuroimmunological link to virus diseases of the central nervous system (CNS). 1989 Autumn Immunology Conference.
- Coons, W.J. and Johnson, T.C. 1990. β -endorphin alters the course of CNS disease of athymic nude mice produced by a temperature-sensitive mutant of vesicular stomatitis virus (VSV) by an interaction with a population of asialo-GM1 bearing lymphocytes. Presented before the Missouri Valley Branch, American Society for Microbiology.

DISTRIBUTION LIST

Behavioral Immunology Program

Annual, Final and Technical Reports (1 copy each except as noted)

INVESTIGATORS

Dr. Itamar B. Abrass Department of Medicine University of Washington Harborview Medical Center Seattle, WA 98104	* Dr. Christopher L. Coe Department of Psychology Harlow Primate Laboratory University of Wisconsin Madison, WI 53715
Dr. Prince K. Arora NIDDK, Bldg. 8, Room 111 National Institutes of Health Bethesda, MD 20892	* Dr. Sheldon Cohen Department of Psychology Carnegie-Mellon Univ. Pittsburgh, PA 15213
* Dr. Andrew S. Baum Dept. of Medical Psychology Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799	Dr. Walla L. Dempsey Dept. of Microbiology and Immunology Medical College of Pennsylvania 3300 Henry Avenue Philadelphia, PA 19129
Dr. Charles A. Bowles Merrifield Research Lab, Inc. P.O. Box 2362 Merrifield, VA 22116-2362	Dr. Robert L. Hunter Dept. of Pathology Emory Univ. School of Medicine WMB 760 Atlanta, GA 30322
Dr. Karen Bulloch Dept. of Pediatrics M009D Univ. of California, San Diego, School of Medicine La Jolla, CA 92093	Dr. Terry C. Johnson Division of Biology Ackert Hall Kansas State University Manhattan, KS 66506
Dr. Michael D. Cahalan Dept. of Physiology and Biophysics Univ. of California, Irvine Irvine, CA 92717	* Dr. Jerome Kagan Dept. of Psychology Harvard University Cambridge, MA 02138
Dr. Donald A. Chambers 801 S. Paulina - Room J30E Univ. of Illinois at Chicago P.O. Box 6998 Chicago, IL 60680	* Dr. Keith W. Kelley Lab. of Immunophysiology University of Illinois 809 S. Wright Street Champaign, IL 61820-6219

Encl(1)

Dr. James M. Krueger
Dept. of Physiology
University of Tennessee
894 Union Street
Memphis, TN 38163

- * Dr. Sandra Levy
WPIC
Univ. of Pittsburgh
School of Medicine
3811 O'Hara Street
Pittsburgh, PA 15213

Dr. Roger M. Loria
Virginia Commonwealth Univ.
Dept. of Microbiology &
Immun. Box 678, MCV Station
Richmond, VA 23298-0001

- * Dr. Lester Luborsky
Dept. of Psychiatry
308 Piersol Bldg. G1
Hospital of the University
of Pennsylvania
Philadelphia, PA 19104

- * Dr. Steven F. Maier
Dept. of Psychology
University of Colorado
Campus Box 345
Boulder, CO 80309

Dr. Diana S. Malcolm
Dept. of Surgery,
Uniformed Services Univ.
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814-4799

Dr. Michael H. Melner
Dept. of Reproductive Biology
Oregon Regional Primate Center
505 N.W. 185th Avenue
Beaverton, OR 97006

Dr. Vera B. Morhenn
Department of Dermatology
Martinez VA
Martinez, CA 94553

Dr. Jose R. Perez-Polo
Dept. of Biochemistry
Gail Borden Bldg., Room 436
Univ. of Texas Medical Branch
Galveston, TX 77550-2777

Dr. Merrily P.M. Poth
Dept. of Pediatrics, A3027
Uniformed Services Univ.
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814-4799

Dr. Eric M. Smith
Dept. of Psychiatry
Univ. of Texas Medical
Branch
Galveston, TX 77550

Dr. G. John Stanton
Dept. of Microbiology
Univ. of Texas Medical
Branch
Galveston, TX 77550

- ** Dr. Ross R. Vickers, Jr.
Naval Health Research Center
Building 346
P.O. Box 85122
San Diego, CA 92138

- * Supported by ONR Code 1142BI
- ** Supported by NMRDC

Annual, Final and Technical Reports (one copy each except as noted)

ADMINISTRATORS

Dr. Jeannine A. Majde, Code 1141SB (2 copies)
Program Manager, Systems Biology
Office of Naval Research
800 N. Quincy Street
Arlington, VA 22217-5000

Program Manager
Biotechnology Program
Office of Naval Research
Code 1213
800 N. Quincy Street
Arlington, VA 22217-5000

Administrator (2 copies) (Enclose DTIC Fm 50)
Defense Technical Information Center
Building 5, Cameron Station
Alexandria, VA 22314

Program Manager
Support Technology Directorate
Office of Naval Technology
Code 223
800 N. Quincy Street
Arlington, VA 22217-5000

Administrative Contracting Officer
ONR Resident Representative
(address varies - obtain from business office)

DoD ACTIVITIES

Commanding Officer
Naval Medical Center
Washington, DC 20372

Commander
USAMRIID
Fort Detrick
Frederick, MD 21701

Commanding Officer
Naval Medical Research & Development Command
National Naval Medical Center
Bethesda, MD 20814

Directorate of Life Sciences
Air Force Ofc of Scient. Res.
Bolling Air Force Base
Washington, DC 20332

Director, Infectious Diseases Program Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Library
Armed Forces Radiation
Research Institute
Bethesda, MD 20814-5145

Commander
Chemical & Biological Sciences Division
Army Research Office, P.O. Box 12211
Research Triangle Park, NC 27709

Commander
U.S. Army Research and Development Command
Attn: SGRD-PLA
Fort Detrick
Frederick, MD 21701

Final and Technical Reports Only

Director, Naval Research Laboratory (6 copies)
Attn: Technical Information Division, Code 2627
Washington, DC 20375